Sweden

Dela

Kontakt

  • AstraZeneca
    Karlebyhus, Astraallén 151 85 SÖDERTÄLJE
    08-553 260 00
    08-553 290 00
    http://www.astrazeneca.se
  • Jacob Lund

    Extern kommunikationsdirektör


    +46 8 - 553 26020
    +46 72 560 21 57
    http://www.astrazeneca.se
  • Lotta Sjösten

    Presskontakt


    + 46 8 553 271 10
    + 46 72 739 60 52
    http://www.astrazeneca.se
  • Petra Eurenius

    Director Corporate Communication - Nordic Marketing Company


    +46 8 552 51396
    +46 70 918 65 62
    http://www.astrazeneca.se
    • Välj datumintervall -

    Katarina Ageborg ny VD  för AstraZeneca i Sverige

    AstraZeneca meddelar i dag att Katarina Ageborg utsetts till ny VD för AstraZeneca AB. Hon tar över efter Jan-Olof Jacke den 1 augusti 2018 och kommer även fortsättningsvis rapportera till koncernchef Pascal Soriot.Katarina Ageborg har suttit i bolagets koncernledning sedan 2011 och fortsätter även i sina nuvarande roller som hållbarhetschef och Chief Compliance Officer. ”Jag är väldigt glad att Katarina nu även kommer ansvara för att utveckla AstraZenecas starka position i Sverige. Samtidigt vill jag tacka Jan-Olof för hans insatser genom många år. Han har varit en framstående

    Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer

    Imfinzi is the only immunotherapy approved for unresectable Stage III NSCLC Approval is based on the Phase III PACIFIC trialAstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi (durvalumab) as maintenance therapy after definitive chemoradiation therapy (CRT) in locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC). Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit said: “Non-small cell lung cancer is a leading cause of

    Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

    Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Second approval in Japan for AstraZeneca and MSD’s LynparzaAstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved Lynparza (olaparib) tablets for use in patients with unresectable or recurrent BRCA-mutated (BRCAm), human epidermal growth factor receptor 2 (HER2) negative breast cancer who have received prior chemotherapy. Patients are selected for therapy based on

    Bydureon receives positive EU CHMP opinion for new BCise device for patients with type-2 diabetes

    New formulation of once-weekly Bydureon in a pre-filled device recommended to help improve glycaemic control   AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending inclusion of Bydureon (2mg prolonged-release suspension for injection) BCise device as a new formulation within the marketing authorisation for Bydureon (exenatide extended-release) for the treatment of type-2 diabetes. The new formulation of once-weekly Bydureon is an improved single-dose, pre-filled

    Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer

    Lynparza met primary endpoint of progression-free survival in women with BRCA-mutated advanced ovarian cancer and showed a safety profile consistent with previous trials AstraZeneca and MSD’s Lynparza is the only PARP inhibitor to demonstrate significant activity in the 1st-line maintenance settingAstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets. Women with BRCA-mutated (BRCAm) advanced

    AstraZeneca to share latest data from a leading portfolio that aims to advance clinical understanding of diabetes and CV risk management at ADA

    Key data evaluating the efficacy and safety of Farxiga (dapagliflozin) in combination with other type-2 diabetes therapies head-to-head vs. insulin or sulfonylurea Latest data from the DEPICT clinical programme evaluating Farxiga to address an unmet need for oral therapy in adult patients with type-1 diabetes Debut of pre-clinical and clinical data for MEDI0382 in type-2 diabetes, a potential first-in-class oxyntomodulin-like peptideAstraZeneca and its global biologics research and development arm, MedImmune, will present 45 abstracts including seven late-breaking data disclosures

    Update on Phase III clinical trials of lanabecestat for Alzheimer’s disease

    Independent data monitoring committee advises lanabecestat is unlikely to meet primary endpoints, leading to decision to discontinue these trialsAstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer’s disease. The decision is based on recommendations by an independent data monitoring committee (IDMC), which concluded that both the AMARANTH trial, in early Alzheimer’s disease, and the DAYBREAK-ALZ trial, in mild Alzheimer’s disease dementia,

    The EU approves Tagrisso for 1st-line treatment of EGFR-mutated non-small cell lung cancer

    1st-line Tagrisso offers a potential new standard of careToday the European Commission has granted marketing authorisation for Tagrisso (osimertinib) as monotherapy for the 1st-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. The approval is based on results from the Phase III FLAURA trial published in the New England Journal of Medicine . Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit

    Lynparza in combination with abiraterone delayed disease progression in metastatic castration-resistant prostate cancer

    Lynparza is the first and only PARP inhibitor to demonstrate activity in combination with standard-of-care treatment in prostate cancer AstraZeneca and MSD presented results of Study 08 at 2018 ASCO Annual Meeting with simultaneous publication in the Lancet OncologyAstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data, which showed clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of care,

    Moxetumomab pasudotox pivotal data in patients with previously-treated hairy cell leukaemia presented at the 2018 ASCO meeting

    Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence of any remaining detectable cancer cells Phase III clinical trial results served as basis for recent US FDA regulatory submissionAstraZeneca and MedImmune, its global biologics research and development arm, today presented results from the Phase III (‘1053’) clinical trial that evaluated moxetumomab pasudotox in 80 patients with relapsed or refractory hairy cell leukaemia (HCL) who had received at least two prior lines of therapy.1 Moxetumomab pasudotox, an

    Update on TERRANOVA Phase III trial for Fasenra in chronic obstructive pulmonary disease

    TERRANOVA trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with chronic obstructive pulmonary diseaseAstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from TERRANOVA, the second of two pivotal Phase III trials for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations. This news follows the announcement earlier this

    Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer

    Imfinzi met the second primary endpoint of overall survival which was both statistically-significant and clinically-meaningful at a planned interim analysisAstraZeneca and MedImmune, its global biologics research and development arm, today announced positive overall survival (OS) results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled, multi-centre trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease had not progressed following platinum-based chemotherapy concurrent with radiation therapy (

    AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline

    91 accepted abstracts at ASCO, including Lynparza in prostate cancer and moxetumomab pasudotox in hairy cell leukaemiaAstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 1-5 June 2018, with an expanded portfolio in Oncology. Having achieved 16 regulatory approvals across major markets (US, EU, Japan and China), AstraZeneca will be sharing its R&D momentum at ASCO with seven “Best of ASCO” presentations and 14 oral presentations from a total of 91 accepted abstracts.

    Regulatory submission in Japan for Forxiga in type-1 diabetes

    Japan submission follows European regulatory submission acceptance in March 2018AstraZeneca has submitted a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Forxiga (dapagliflozin), a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D). The Japan sNDA is based on Phase III data from the DEPICT (Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes) clinical programme for Forxiga in T1D and a dedicated trial

    Lokelma approved in the US for the treatment of adults with hyperkalaemia

    Lokelma provides rapid and sustained potassium control for patients in a condition with high unmet needThe US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults with hyperkalaemia,1 a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.2 The risk of hyperkalaemia increases significantly for patients with chronic kidney disease (CKD) and for those who take common medications for heart failure (HF), such as renin-angiotensin-

    AstraZeneca PLC:s resultatrapport för första kvartalet 2018

    Bra lanseringar och resultat för våra nyare läkemedel stödjer oförändrad prognosSom förväntat hade produktförsäljningen fördel av starka lanseringar, samt den fortsatta tillväxten av nyare mediciner och tillväxten i Kina, men påverkades negativt av den minskade försäljningen av Crestor. Framsteg gjordes avseende den övergripande kostnadsdisciplinen medan nivån på intäkterna från externa samarbeten, tajmingen för avyttringar och satsningen på lanseringar påverkade nivån på det övergripande resultatet. Patienter fortsätter att dra nytta av framstegen i vår forskningsportfölj och AstraZeneca

    New England Journal of Medicine publishes two trials for Symbicort as an anti-inflammatory reliever therapy ‘as needed’ in mild asthma

    AstraZeneca today announced results from the Phase III SYGMA  trials1 ,2  of Symbicort Turbuhaler (budesonide/formoterol) given as an anti-inflammatory reliever ‘as needed’ versus two different treatment regimens in patients with mild asthma. The data are published in the New England Journal of Medicine1,2 and will be presented on Sunday 20

    AstraZeneca is advancing clinical practice in respiratory medicine with new data at the American Thoracic Society 2018 International Congress

    Phase III SYGMA trials investigated the value of Symbicort Turbuhaler taken as an anti-inflammatory reliever therapy ‘as needed’ in mild asthma   A growing body of evidence on Fasenra’s role in severe eosinophilic asthma supports improved identification of suitable patientsAstraZeneca and MedImmune, its global biologics research and development arm, will present updates from its respiratory medicines and pipeline at the American Thoracic Society (ATS) 2018 International Congress, 18-23 May in San Diego, US. The breadth and depth of science are reflected in the 60 accepted abstracts,

    AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease

    GALATHEA Phase III trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD Second Phase III trial TERRANOVA is ongoing with results expected later this quarterAstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in

    Lynparza tablets receive EU approval for the treatment of platinum-sensitive relapsed ovarian cancer

    Women with platinum-sensitive ovarian cancer now have access to maintenance therapy with AstraZeneca and MSD’s Lynparza, regardless of BRCA status Lynparza has over five years’ efficacy and safety follow-up data New formulation reduces dosing to two tablets twice dailyAstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the European Medicines Agency (EMA) has approved Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian,

    AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets

    AstraZeneca to receive upfront payment and future paymentsAstraZeneca has entered into an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa. The transaction is part of AstraZeneca’s strategy to focus on its three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. Seroquel, used primarily to treat schizophrenia and bipolar

    Ny studie: Patienter med svår astma träffar sällan en läkare trots att varannan patient har en okontrollerad sjukdom

    Tisdagen den 1 maj infaller världsastmadagen, en dag som syftar till att uppmärksamma och informera om astma, en av våra vanligaste folksjukdomar. Världsastmadagen sammanfaller även med pollensäsongen som nu tagit fart och som innebär en svår tid för många med astma. I Sverige är cirka 800 000 människor drabbade av astma och av dessa har cirka 4 procent svår astma[1] . De flesta patienter med astma kan med de behandlingsalternativ som erbjuds leva ett relativt normalt liv. För patienter med en svår och okontrollerad astma är tyvärr situationen en annan visar den största

    Tagrisso receives positive EU CHMP opinion for 1st-line treatment of EGFR-mutated non-small cell lung cancer

    Recommendation based on FLAURA trial data showing unprecedented median progression-free survival of 18.9 months for Tagrisso versus 10.2 months compared with current standard of care The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending a change to the terms of the Marketing Authorisation for Tagrisso (osimertinib) to include the 1st-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. The

    Det finns inga träffar som matchar nuvarande filter
    Det finns inga fler träffar som matchar nuvarande filter
    Tillbaka till sidans topp

    Prenumerera

    Multimedia